首页 / 产品 / 蛋白 / 活性蛋白

Recombinant E.coli flaA protein

  • 中文名: 空肠弯曲杆菌鞭毛杆菌A(flaA)重组蛋白
  • 别    名: flaA;CARD12;CLAN;CLAN1;NLR family CARD domain-containing protein 4
货号: PA2000-3096
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属E.coli
靶点flaA
Uniprot No Q46113
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间 2-575aa
氨基酸序列GFRINTNVAALNAKANADLNSKSLDASLSRLSSGLRINSAADDASGMAIKDSLRSQANTLGQAISNGNDALGILQTADKAMDEQLKILDTIKTKATQAAQDGQSLKTRTMLQADINRLMEELDNIANTTSFNGKQLLSGNFINQEFQIGASSNQTVKASIGATQSSKIGLTRFETGSRISVGGEVQFTLKNYNGIDDFKFQKVVISTSVGTGLGALADEINKNADKTGVRATFTVETRGMGAVRAGATSDDFAINGVKIGKVDYKDGDANGALVSAINSVKDTTGVEASIDENGKLLLTSREGRGIKIEGNIGRGAFINPNMLENYGRLSLVKNDGKDILISGTNLSAIGFGTGNMISQASVSLRESKGQIDANVADAMGFNSANKGNILGGYSSVSAYMSSTGSGFSSGSGFSVGSGKNYSTGFANTIAISAASQLSAVYNVSAGSGFSSGSNLSQFATMKTSAGNTLGVKDETAGVTTLKGAMAVMDIAETAITNLDQIRADIGSVQNQVTSTINNITVTQVNVKAAESQIRDVDFAAESANYSKANILAQSGSYAMAQANSVQQNVLRLLQ
预测分子量 60.4 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于 **flaA重组蛋白** 的3篇参考文献示例(内容基于公开研究概括,具体文献需根据实际数据库检索):

---

1. **标题**: *"Expression and immunogenicity of a recombinant Campylobacter jejuni FlaA protein in chickens"*

**作者**: Guerry P, et al.

**摘要**: 研究报道了空肠弯曲杆菌(*Campylobacter jejuni*)鞭毛蛋白FlaA的重组表达及其在鸡模型中的免疫原性,证明其作为候选疫苗可诱导特异性抗体并降低肠道定植。

2. **标题**: *"Cloning and characterization of Helicobacter pylori FlaA as a diagnostic antigen"*

**作者**: Yeh HY, et al.

**摘要**: 通过克隆表达幽门螺杆菌(*Helicobacter pylori*)的FlaA蛋白,评估其作为血清学诊断抗原的潜力,结果显示高特异性和敏感性,适用于感染检测。

3. **标题**: *"Recombinant FlaA from Listeria monocytogenes elicits protective immunity in murine models"*

**作者**: Drolia R, et al.

**摘要**: 利用重组单核细胞增生李斯特菌(*Listeria monocytogenes*)FlaA蛋白免疫小鼠,证实其通过激活TLR通路引发Th1型免疫应答,显著提高对李斯特菌感染的保护力。

---

建议通过 **PubMed** 或 **Web of Science** 检索最新文献,关键词可组合 *"recombinant FlaA protein"* 或 *"FlaA vaccine/diagnosis"*。

背景信息

**Background of FlaA Recombinant Protein**

The FlaA protein is a major structural component of bacterial flagella, primarily identified in *Campylobacter jejuni*, a leading cause of bacterial gastroenteritis worldwide. Flagella are critical for bacterial motility, host colonization, and pathogenesis. FlaA, as the dominant flagellin subunit, plays a pivotal role in assembling the flagellar filament and contributes to immune evasion by undergoing antigenic variation. Its immunogenic properties and surface exposure make it a key target for diagnostic and vaccine development.

Recombinant FlaA is produced through genetic engineering, where the *flaA* gene is cloned into expression vectors (e.g., *E. coli*) and purified via affinity chromatography. This approach ensures high-yield, contamination-free protein production, bypassing challenges associated with native protein extraction from pathogenic strains.

Research on FlaA recombinant protein focuses on multiple areas:

1. **Vaccine Development**: FlaA’s immunogenicity drives studies exploring its use as a subunit vaccine candidate. Animal models show antibodies against FlaA can reduce *C. jejuni* colonization.

2. **Diagnostic Tools**: FlaA serves as an antigen in serological assays to detect *C. jejuni* infections, improving diagnostic accuracy.

3. **Pathogenesis Studies**: Recombinant FlaA aids in elucidating mechanisms of bacterial motility, host-cell interactions, and immune responses.

4. **Biotechnology**: Engineered FlaA variants are investigated for nanocarrier systems or adjuvant applications due to their self-assembling properties.

Despite progress, challenges remain, including understanding strain-specific FlaA diversity and optimizing stability for clinical use. Ongoing studies aim to harness FlaA’s potential in combating *Campylobacter*-related diseases and advancing biotechnological innovations.

客户数据及评论

折叠内容

大包装询价

×